Statistics from Altmetric.com
Breathing modification techniques may have a useful role in the management of asthma
Treatments involving the manipulation of breathing are commonly used in routine practice by physiotherapists and other practitioners in a variety of clinical settings1 yet, despite decades of use, there is no robust evidence base to confirm the effectiveness of these activities. Practical and logistic difficulties exist in the design and execution of the randomised controlled clinical trials required to provide the highest grade evidence for such treatments. While the design of studies investigating pharmacological agents is relatively straightforward, there are numerous potential pitfalls in trials investigating complex interventions such as breathing therapies which require significant interaction between patient and practitioner. There are obvious difficulties with devising suitable controls, blinding participants and researchers to any intervention received, and in ensuring standardisation. While it is frequently clinically acceptable to standardise medication dosage and timing, it is not normal to do so for breathing therapies—in which the response of the individual affects the intervention provided during any interaction between patient and practitioner.
STUDY OF BREATHING TECHNIQUES
In this issue of Thorax, Slader et al2 present the results of a randomised double blind controlled trial comparing two breathing techniques for patients with stable but suboptimally controlled asthma. Fifty seven subjects were randomly allocated to one of two groups receiving instruction in breathing technique from educational videos, and 48 subjects completed the 30 week study. The first group of 28 subjects were instructed in a technique designed to be “active” by mimicking the hypoventilation and nasal breathing strategies advocated by the exponents of the Butekyo breathing method, and the second group of 29 subjects received an instructional video that was intended to be a more neutral control, consisting of upper chest exercises and “control of breathing” exercises focusing on posture and relaxation. Subjects were instructed to practise the exercises twice daily and as needed for relief of symptoms. Strictly speaking, this was a negative study in that no clinically important differences were observed between the groups following the interventions; however, a marked reduction in the use of short acting β2 agonist bronchodilator medication was seen in both groups compared with the baseline period, without significant changes in lung function, airways hyperreactivity, or end tidal CO2. Although there were no differences between groups for changes in patient centred outcomes such as quality of life and Asthma Control Questionnaire scores, consistent trends were seen with improvements in both groups over the baseline period. These improvements were maintained over 28 weeks in spite of a second phase of back-titration of inhaled corticosteroids which achieved a 50% reduction in dose that was similar in both groups. Although a reduction in inhaled corticosteroid dose without a loss of control is welcome news, as the authors state it cannot be assumed that this is a result of the breathing exercises; it is recognised that many patients with asthma are overtreated and recent step-down studies have reported similar dose reduction without the use of any intervention.3
Of more interest is the reduction in bronchodilator use. Previous trials involving breathing therapies for asthma have also reported a reduction in rescue medication usage, although not of this magnitude. If individuals were able to reduce their bronchodilator usage by the amount reported (86%) without any accompanying deterioration in their asthma control, this is worthy of comment. The authors have suggested some possible mechanisms for this, including the possibility that the two breathing routines provided a non-specific deferral strategy for β2 agonist use.
This study raises important questions about the design of trials investigating the effectiveness of breathing therapies, and on strategies for reducing bronchodilator use without compromising asthma outcomes.
PROBLEMS OF TRIAL DESIGN
Designing any convincing yet inert placebo intervention for breathing therapy is extremely challenging. Previous authors have used controls involving other breathing manoeuvres, relaxation, education, videos, and sham training devices.4–,7 There are problems with nearly all of these. We currently have minimal understanding of the physiological or psychological effects of any of the respiratory manoeuvres used in clinical practice.8 Relaxation techniques themselves invariably involve some modulation of breathing pattern, and “breathing control” will also incorporate relaxation techniques.9 Slader et al have addressed the issues of standardisation and patient-practitioner interaction by providing both the intervention and control technique via a video. Unfortunately, this results in a rather simplistic approach to a fairly complex intervention, as to teach any form of exercise effectively requires not only initial demonstration and subsequent practice but also feedback on individual performance to ensure conformity with the prescribed exercise. Although videos have been used in previous trials of breathing techniques, there is some evidence that viewing a television screen in itself may have a relaxing effect and alter breathing patterns in comparison with other sedentary activities such as reading.10
In the study by Slader et al, a supposedly active intervention involving “hypoventilation”, “breath holding”, and “nasal breathing“—a package that closely mimics the main elements of the Butekyo breathing technique11—is compared with a control involving “non-specific upper body exercises”. However, on closer examination the latter included “controlled inspiratory-expiratory cycles” during arm exercises as well as “control of breathing” and “relaxation”. This means that both arms of the trial involved altering breathing patterns, although—as is common with most trials of breathing therapy—the interventions are not described in sufficient detail to permit accurate replication. Terms like “control of breathing” can be interpreted in many ways, but techniques generally involve asking people to breathe at a slower than normal rate and/or at reduced volumes and flows. Unfortunately, this suggests manipulation of breathing patterns in a way similar to many active therapies, and this control intervention may not have been inert. It is therefore possible that the similar reduction in bronchodilator use seen in the two study arms may have resulted from two equally effective therapies, rather than indicating a lack of effect in the “active” treatment group.
Interventions to alter patterns of breathing are most likely to work in patients in whom the underlying breathing pattern is in some way abnormal. Direct evidence for clinically significant altered patterns of breathing in asthma patients is not available, although some studies have indicated that patients with stable asthma are hypocapnic.12,13 Obtaining direct evidence of dysfunctional breathing has historically been very difficult, as use of mouthpieces/masks inevitably affects breathing patterns, and observations in a laboratory setting may induce anxiety leading to hyperventilation in some patients.14 Indirect evidence comes from surveys of asthma patients reporting up to 30% prevalence of “dysfunctional breathing” when assessed using the Nijmegen hyperventilation questionnaire.15,16 A small trial of physiotherapy breathing retraining targeting such patients showed clinically significant improvements in quality of life in over half the subjects.4 Recent technological improvements are currently making non-invasive ambulatory measurement during daily activity into a practical possibility.17 This should provide us with more information about patterns of breathing in asthma and enable us to identify those with dysfunctional breathing. Future trials of breathing therapies could then be targeted specifically at this group. The same technology has the potential to provide baseline and outcome measures for breathing therapies to establish whether any genuine change in breathing pattern has occurred.
REDUCED USE OF β2 AGONISTS
An observed reduction in β2 agonist use of almost 90% is of interest, particularly at a time when the safety profile of β agonists has once again come under the spotlight.18 There have been concerns for some time that high levels of use of short acting β2 agonists may be associated with an increased risk of severe asthma attacks and death,19 although it remains uncertain as to whether this represents a pharmacological risk or acts as a marker for more severe and uncontrolled asthma.20 There is evidence that frequent administration of short acting β2 agonists results in some loss of bronchodilation21–,23 and a decrease in bronchoprotective action,24 particularly in patients with certain genotypes of the β2 adrenergic receptor.25 In addition, discontinuation of frequent β agonist use may result in a transient rebound decrease in pulmonary function and increase in bronchial hyperresponsiveness.23 Regular exposure to inhaled β agonists may have detrimental cardiac effects, particularly on those with pre-existing cardiac disease.26 There is therefore a good case to be made for any intervention, particularly a non-pharmacological one, which can reduce rescue bronchodilator use without compromising asthma control.
Was the reduction in bronchodilator use a result of the breathing exercises in the two arms of the study or was it due to other non-specific mechanisms? The subjects recruited to this study were clinically stable but had a relatively high bronchodilator use at baseline (3 puffs per day) so “regression to the mean” and trial involvement effects may explain some of the reduction, although the magnitude of the reduction and the rapidity of the effect which commenced immediately after the beginning of the intervention and continued to improve over the initial 12 week study phase make it unlikely this could be a full explanation. Subjects in both groups were instructed when symptomatic to use their breathing exercises for up to 5 minutes before using rescue medication, so it is possible that the medication reduction resulted from a short deferment of use of rescue bronchodilator and allowed spontaneous resolution of symptoms, rather than from a specific effect of the exercises. If this were the case, a viable deferment strategy could be applicable to many asthmatics, and giving instructions on deferment of bronchodilator use plus provision of an acceptable alternative action such as a breathing exercise (even if this is physiologically inert) may be valuable. Further studies are needed to confirm the reliability and generalisability of these findings, which potentially have considerable significance for asthma management, and to investigate the mechanisms of apparent effectiveness of these two breathing exercise programmes.
This study poses more questions than it answers, but does again raise the possibility that breathing modification techniques may have a useful role to play in the management of asthma—which patients may be helped, which techniques are most effective, and by what mechanism of action still remain to be clarified.
Competing interests: none declared.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.